TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370354

Intervention type: BEHAVIORAL
Intervention: Observational
Description: Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
Study: NCT02636868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant delivered via investigational delivery device
Description: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
Study: NCT02250664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Very low nicotine content cigarettes
Study: NCT02111551

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMXB-A 150 mg
Study: NCT02250664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Very low nicotine content cigarettes
Study: NCT03275948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain
Description: whole grain rye

Intervention type: OTHER
Group type: OTHER
Intervention: reference
Description: white wheat bread
Study: NCT03381417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegcyte
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulastim
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study: NCT02721108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
Study: NCT02111551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02721108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation app
Description: The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
Study: NCT01998191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (nurse)
Description: A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (nurse)
Description: A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (nurse)
Description: A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (physician)
Description: A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (physician)
Description: A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
Study: NCT02111551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMXB-A 75 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMXB-A 75 mg
Study: NCT01998191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (physician)
Description: A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
Study: NCT00523900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quaker Complete Nutrition Supplements
Description: 3-6 250ml cans of Quaker Complete Nutrition Supplements per day
Study: NCT02128269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study Drug- ALXN1007
Description: 10 mg/kg IV q 2 weeks x 12 doses
Study: NCT03110809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoid
Description: Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoid
Description: Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for capsinoid. Capsule contains no active ingredients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for capsinoid. Capsule contains no active ingredients.
Study: NCT01998191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (MDT)
Description: A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (MDT)
Description: A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explicit case note review checklist (MDT)
Description: A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms.
Study: NCT01171586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mDiet
Description: The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mDiet
Description: The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics.
Study: NCT01852383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial.
Study: NCT02099201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 200 mg
Description: Predicted dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 200 mg
Description: Predicted dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 200 mg
Description: Predicted dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 800 mg
Description: Predicted dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 (Group C1 dose to be selected)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-389949 (Group C2 dose to be selected)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02144155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin: 24IU - 168 IU
Description: Oxytocin: 24IU - 168 IU
Study: NCT03165305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Description: Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
Study: NCT01663298

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.

Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
Study: NCT00527722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Seal Track Plug
Description: The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No lung plug
Description: Standard lung biopsy without placement of the plug.
Study: NCT03708042

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study: NCT05015842

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical Therapy
Description: This is a combine protocol of different therapeutic exercises and heat therapy.
Study: NCT02144155

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxytocin: 24IU - 168 IU
Description: Oxytocin: 24IU - 168 IU

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: placebo drug
Study: NCT02718014

Intervention type: OTHER
Group type: OTHER
Intervention: scaling and root planing (srp)

Intervention type: OTHER
Group type: OTHER
Intervention: scaling and root planing (srp)
Study: NCT03158350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructed Brushing Method
Description: Stationary Bristle Technique
Study: NCT01167166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
Study: NCT02092402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplantation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal transplantation
Study: NCT02636868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant delivered via investigational delivery device
Description: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP
Description: Nasal CPAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP
Description: Nasal CPAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Nasal CPAP
Study: NCT02141282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
Study: NCT05015842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: This is a combine protocol of different therapeutic exercises and heat therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tapping
Description: Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
Study: NCT01273298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
Study: NCT01021748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Oral tablets
Study: NCT03465553

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
Study: NCT00026377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50 mg daily for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg 3 times daily for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: 3.6 mg once a month for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 7.5 mg once a month for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU5416
Description: IV infusion at assigned dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: daily for 5 days each week
Study: NCT02211573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, Aerobic (Water based)
Description: Patients of this group were submitted to an aerobic water based physical training
Study: NCT01840254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT02887755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS) Sensor
Description: These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
Study: NCT01021748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Oral tablets
Study: NCT03708042

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Radiochemotherapy
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study: NCT01718847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120101 (Poziotinib)
Description: 16 mg PO once daily until disease progression or unacceptable toxicity development
Study: NCT02152579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Description: Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
Study: NCT00002670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT03184805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuing aspirin
Description: Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stopping aspirin
Description: Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
Study: NCT00002670

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy
Study: NCT00514020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: through a vein over 2 hours on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 500 ml D5W through a vein over 2 hours on days 1 and 15.